Date: 2014-08-25
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the HPV 2014 conference in Seattle
Company: Genomic Vision (France)
Product: HPV diagnostic test using the DNA molecular combing process
Action
mechanism: DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if “combed”, and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient’s genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.
Disease: human papillomavirus (HPV) infection
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On August 25, 2014, Genomic Vision has presented the first results of its development program for a test to detect the Human Papilloma Virus (HPV) in cervical cancer. Results were presented in the form of a poster at the 29th edition of the HPV conference (International Papillomavirus Conference and Clinical & Public Health Workshops), in Seattle. The preliminary results have shown that molecular combing technology allows the direct and high-resolution visualization of the integration of high-risk HPV genomes (HPV16 and HPV18 as unique or tandem array) in the cervical-cancer-derived cell lines and in the cervical smears of patients with lesions at various stages of the disease’s evolution. These results also highlight the possibility of exploring the integration of high-risk HPV genomes at individual locus level, such as that of the c-Myc oncogene involved in controlling cellular proliferation.
